Cefpodoxime

such as community-acquired pneumonia, acute otitis media, sinusitis, pharyngitis and tonsillitis, etc.

The global market size of cefpodoxime has maintained steady growth in recent years, reaching approximately USD 1.18 billion in 2020, with a compound annual growth rate of around 3.2% from 2021 to 2027. In the generic drug market, Indian and Chinese enterprises occupy the dominant supply position, accounting for 72% of the total supply in 2020. In China, the number of winning enterprises for cefpodoxime preparations in the national centralized drug procurement expanded to 9 in 2021, with an average price reduction of 68% for the winning products, which further drives the clinical popularization of oral cephalosporin drugs.

The original developer of cefpodoxime is Shionogi & Co., Ltd. of Japan, with the original brand name "Banan". The core compound patent expired in 2004 in Japan, and expired in 2006 in major European and American markets. The main dosage form of the original product is tablet, with two specifications of 100mg and 200mg, which have been included in the *Catalogue of Reference Listed Drugs of Chemical Drugs* of China and the reference listed drug catalogue of the US FDA. At present, 23 domestic enterprises in China have obtained CDE registration for cefpodoxime active pharmaceutical ingredients, and nearly 50 cefpodoxime proxetil oral preparations have been approved for marketing. (Data as of July 2022, please refer to the official website of CDE for the latest information)

CATO can provide a full set of cefpodoxime impurity reference standards. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Most impurities are in sufficient stock, and orders placed before 16:00 can be shipped on the same day, providing full-chain reference standard support for pharmaceutical enterprises in process research and development, quality research and quality stability study.